CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 30 enrolled
Drug / intervention
Carvedilol CR +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00657241
NCT00657241Phase 3Completed
CompareCT.gov

Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril

State University of New York at Buffalo·interventional·Posted Apr 14, 2008·Updated May 27, 2022

In Brief

A Phase 3 clinical trial evaluating Carvedilol CR and Valsartan for Hypertension. Completed, enrolled 30 participants across 1 site.

Detailed Summary

14-week single blind, double baseline, forced-titration, cross-over comparison of the cardiac benefits of Coreg CR compared to valsartan added to existing ACE inhibition

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
CollaboratorsGlaxoSmithKline

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 14, 2008
Enrollment StartApr 1, 2008
Primary CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 18.2 years ago

Interventions

Carvedilol CRdrug

Valsartandrug